The current timeline is in the investor deck for 18-MC. They expect the phase 3 trial to start at the end of 2023 and be finished by the end of 2024. Now obviously there could be delays and take longer or there could be breakthrough therapy designation and get done faster.
Market Data 
Markets 
AI
